Artesunate (Ridsunate) is an intravenous anti-malarial drug indicated for the initial treatment of severe malaria in adults and children. Although it has significant efficacy, vigilance is required regarding its potential side effects and special medication precautions.

What Are the Side Effects of Artesunate (Ridsunate)?

Common Adverse Reactions in Adult and Pediatric Patients

Hematological system: Anemia (65%), hemoglobinuria (6.7%), thrombocytopenia (18%).

Liver abnormalities: Elevated transaminases (27%), jaundice (2.3%), hyperbilirubinemia (14%).

Renal impairment: Acute renal failure (8.9%), with some patients requiring dialysis treatment.

Others: Acute respiratory distress syndrome (8%), diarrhea (3%), neutropenia (5%).

Severe Side Effects of Artesunate (Ridsunate) Requiring Vigilance

Post-Treatment Hemolytic Anemia

Manifestations: Hemoglobin decrease, haptoglobin reduction, and lactate dehydrogenase elevation may occur 7 days after treatment; blood transfusion may be required in severe cases.

Monitoring: Regular monitoring of hemoglobin and hemolysis indicators is necessary within 4 weeks after treatment.

Allergic Reactions and Anaphylactic Shock

Manifestations: Urticaria, angioedema, dyspnea, and even shock.

Management: Immediately discontinue the drug and switch to other anti-malarial drugs.

Embryo-fetal toxicity (animal data): Animal studies have shown that a single intravenous administration can cause embryonic death.

Risk reminder: Although human data on use during pregnancy are limited, the maternal and fetal risks of severe malaria must be weighed when using the drug in pregnant women.

Precautions for Using Artesunate (Ridsunate)

Medication in Special Populations

Pregnancy: Treatment for severe malaria should not be delayed due to pregnancy, but potential risks must be informed to the patient.

Children: The dosage for children aged ≥ 6 months is the same as that for adults; careful assessment is required for infants aged < 6 months.

Hepatic and renal impairment: No dosage adjustment is needed, but close monitoring is required.

Contraindications and Drug Interactions

Absolute contraindication: Severe allergy to artesunate (e.g., anaphylactic shock).

Interaction management: Avoid concurrent use with pimozide (due to the risk of QT interval prolongation); when used in combination with dexamethasone, the dose of artesunate should be reduced by 50%.

Preparation and Storage

Preparation method: 110 mg of lyophilized powder for injection should be dissolved with 11 mL of the accompanying diluent; gently shake until clear, and use within 1.5 hours.

Storage conditions: Store the unconstituted drug away from light at 20-25°C; the reconstituted solution must not be frozen.

Patient Education

Complete the treatment course: After intravenous treatment, sequential oral anti-malarial drugs (e.g., 8-aminoquinoline derivatives to prevent the recurrence of vivax malaria) must be administered.

Monitoring requirements: Regular rechecks of blood routine and hemolysis indicators are required within 4 weeks after treatment.